Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Latest Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Free seminar to help parents understand signs and characteristics of ADHD

Learning Lab, Brentwood will present a free seminar, Does My Child Have ADHD? Diagnosing and What's Next?, on Thursday June 24, 2010 from 7:00-8:00 PM at the Maryland Farms YMCA in Brentwood. The seminar will be presented by Dr. David Elkins, Clinical Psychologist and Supervising Psychologist of Learning Lab, and Vanessa Adams, School Psychologist of Learning Lab, Brentwood.

24 Jun 2010

Study finds anxiety/panic disorder as most-disabling psychiatric disorder associated with TS

An assessment of patients with adult Tourette syndrome (TS) to identify clinical factors that contribute to psychosocial and occupational disabilities resulting from the vocal or motor tics that define TS found that anxiety/panic disorder may be the most disabling psychiatric condition associated with the disorder.

18 Jun 2010

New data shows Ohio children with special health care needs have inadequate insurance coverage

A third of Ohio children with special health care needs have unstable or inadequate insurance coverage despite the fact that they may qualify for government health programs, according to a new data analysis by the Child Policy Research Center at Cincinnati Children's Hospital Medical Center.

16 Jun 2010

Kendle offers BNA imaging technology for monitoring brain electro-physiological network activity

Kendle, a leading, global full-service clinical research organization, today announced it now offers Brain Network Activation imaging providing a non-invasive platform for mapping, monitoring and understanding brain electro-physiological network activity in response to cognitive or physiological stimuli. The BNA imaging technology was developed by ElMindA, a medical technology development company based in Herzliya, Israel.

15 Jun 2010

Healthcore Media launches dynamic, educational and community-oriented health website

Healthcore Media, LLC has launched http://www.onehealth.com, a dynamic, educational and community-oriented health website that is quickly taking center stage among health portals. Chronic illnesses are at an all-time high, and unbiased medical information and supportive connections with others are taking top priority across the world. One Health has answered the call.

14 Jun 2010

Study finds 18% of pediatric patients at-risk for sleep-related breathing disorders

According to new research that will be presented on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, an estimated 18 percent of pediatric patients in a University of North Carolina-based study were at-risk for sleep-related breathing disorders (SRBD). Importantly, pediatric risk was not associated with any demographic or craniofacial characteristics, as it is in adults, making it difficult to detect.

5 Jun 2010

Socioeconomic factors predict ADHD-medication in Swedish schoolchildren

A major study of more than a million children has found strong links between receiving medication for attention deficit hyperactivity disorder (ADHD) and limited maternal education, single parent families and welfare benefits, according to the June issue of Acta Paediatrica.

1 Jun 2010

Study demonstrates efficacy of CONCERTA in treating ADHD in presence of comorbid learning disability

Turning in assignments, following instructions and focusing on learning something new are among the daily classroom challenges for children with Attention Deficit Hyperactivity Disorder (ADHD), according to the National Institute of Mental Health (NIMH). New data presented today show efficacy of CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) on ADHD symptoms in children with the condition who also may face other specific challenges.

26 May 2010

Shire announces study results of Vyvanse Capsules CII for treatment of ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, today announced the results of a study evaluating the safety and efficacy of Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder in adolescents aged 13 to 17 years.

26 May 2010

New findings on INTUNIV Extended Release Tablets presented at major psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, today announced new findings on once-daily INTUNIV (guanfacine) Extended Release Tablets, the first selective alpha-2A agonist approved for the treatment of Attention Deficit Hyperactivity Disorder, at a major psychiatric meeting.

24 May 2010

New clinical procedures, better diagnostics improve prognosis for children born with severe acute asphyxia

The prognosis for children born with severe acute asphyxia has improved in recent years owing to new clinical procedures and better diagnostics, according to a new doctoral thesis from the Swedish medical university Karolinska Institutet. By measuring levels of lactic acid in the blood during childbirth and the brain activity of the newborn afterwards, doctors can make a much more reliable assessment of the risk of serious brain damage.

21 May 2010

Drug trend for children increased 10.8% in 2009 across America

In growing numbers, children across America are adding a dose of medicine to their daily routine. In 2009, drug trend for children – a measure of prescription spending growth – increased 10.8 percent, driven by a 5 percent increase in drug utilization and higher medication costs, according to the Medco 2010 Drug Trend Report. The growth in prescription drug use among children was nearly four times higher than the rise seen in the overall population.

20 May 2010

Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).

19 May 2010

Study demonstrates need for understanding societal, economic impact of growing medicalization

Menopause. Normal pregnancy. Infertility. ADHD. Erectile dysfunction. Over the last several decades, these conditions have come to be defined and treated as medical problems. They've been "medicalized." In the first study of its kind in the current issue of Social Science and Medicine, Brandeis researchers used national data to estimate the costs of these and a handful of other common conditions on escalating U.S. healthcare spending.

19 May 2010

Exosure to organophosphate pesticides associated with increased risk of ADHD in children

Following closely on the heels of the President's Cancer Panel Report exhorting consumers to choose food grown without pesticides or chemical fertilizers, antibiotics, and growth hormones to help decrease their exposure to environmental chemicals that can increase their risk of contracting cancer, a study published in today's issue of the journal Pediatrics concludes that exposure to organophosphate pesticides at levels common among U.S. children may contribute to the prevalence of attention deficit hyperactivity disorder in these children.

18 May 2010

Cortex first-quarter net income increases to $0.08 per share

Cortex Pharmaceuticals, Inc. reported net income of approximately $5,596,000, or $0.08 per share for the quarter ended March 31, 2010 compared with a net loss of $3,168,000, or $0.07 per share for the corresponding prior year period, with the difference reflecting revenues from the Company's March 2010 transaction with Biovail Laboratories International SRL (Biovail).

17 May 2010

Intellipharmaceutics announces dismissal of patent litigation settlement on Focalin XR drug

Intellipharmaceutics International Inc. and its wholly owned subsidiary Intellipharmaceutics Corp. today announced that it and its licensee and development partner Par Pharmaceutical, Inc. ("Par") have received confirmation that the previously announced stays of the patent litigation concerning a generic version of Novartis' Attention Deficit Hyperactivity Disorder drug, Focalin XR®, (dexmethylphenidate hydrochloride), have expired without regulatory intervention, and that the parties have stipulated to a dismissal of the litigation.

15 May 2010

Computerized model for treating nicotine addiction wins first place at ISEF science competition

A project using cutting edge computer modeling to identify potential new medications for nicotine addiction won first place distinction at the annual Addiction Science Awards at this year's Intel International Science and Engineering Fair (ISEF) --- the world's largest science competition for high school students.

15 May 2010

Gene variations may increase risk of developing schizophrenia: Study

By analyzing the genomes of patients with schizophrenia, genetics researchers have discovered numerous copy number variations—deletions or duplications of DNA sequences—that increase the risk of developing schizophrenia. Significantly, many of these variations occur in genes that affect signaling among brain cells.

11 May 2010

Researchers to identify rare genetic mutation to produce histamine against TS

A single, very unusual family with Tourette syndrome has led Yale School of Medicine researchers to identify a rare mutation in a gene that is required to produce histamine. The finding provides a new framework to understand many years of data on the role of histamine function in the brain and points to a potentially novel approach to treatment of tics and Tourette.

6 May 2010

Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Latest Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Free seminar to help parents understand signs and characteristics of ADHD

Study finds anxiety/panic disorder as most-disabling psychiatric disorder associated with TS

New data shows Ohio children with special health care needs have inadequate insurance coverage

Kendle offers BNA imaging technology for monitoring brain electro-physiological network activity

Healthcore Media launches dynamic, educational and community-oriented health website

Study finds 18% of pediatric patients at-risk for sleep-related breathing disorders

Socioeconomic factors predict ADHD-medication in Swedish schoolchildren

Study demonstrates efficacy of CONCERTA in treating ADHD in presence of comorbid learning disability

Shire announces study results of Vyvanse Capsules CII for treatment of ADHD in adolescents

New findings on INTUNIV Extended Release Tablets presented at major psychiatric meeting

New clinical procedures, better diagnostics improve prognosis for children born with severe acute asphyxia

Drug trend for children increased 10.8% in 2009 across America

Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD

Study demonstrates need for understanding societal, economic impact of growing medicalization

Exosure to organophosphate pesticides associated with increased risk of ADHD in children

Cortex first-quarter net income increases to $0.08 per share

Intellipharmaceutics announces dismissal of patent litigation settlement on Focalin XR drug

Computerized model for treating nicotine addiction wins first place at ISEF science competition

Gene variations may increase risk of developing schizophrenia: Study

Researchers to identify rare genetic mutation to produce histamine against TS

Industry Focus eBook - Pharmaceutical manufacturing (2nd edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Latest Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Industry Focus eBook - Pharmaceutical manufacturing (2nd edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in